Q开关1064nm激光联合氨甲环酸治疗黄褐斑临床观察

目的探讨Q开关1064nm激光联合氨甲环酸治疗黄褐斑的临床疗效和安全性。方法100例黄褐斑患者随机分为两组,每组50例。A组接受Q开关106411113激光治疗,同时口服氨甲环酸;B组单纯接受Q开关1064nm激光治疗。经过3个疗程治疗后观察疗效及不良反应。结果A组基本治愈率46％,有效率74％：B组基本治愈率18％,有效率30．2％,两组疗效差异有统计学意义（P〈0．05）。口服氨甲环酸8个月未见严重不良反应。结论口服氨甲环酸可提高Q开关1064nm激光治疗黄褐斑的临床疗效,且不良反应小。     

氨甲环酸片联合Q开关YAG激光治疗黄褐斑疗效观察

目的：观察氨甲环酸片联合Q开关YAG激光对黄褐斑的治疗效果。方法：选取2006年3月～2011年3月间在我院确诊的黄褐斑患者（150例）为研究对象,随机分为治疗组和对照组,治疗组采用氨甲环酸片加Q开关YAG激光治疗,对照组仅予以Q开关YAG激光治疗,两组均同时辅以中药面膜外敷。治疗3～12个月,随访6～12个月,观察治疗后的临床效果、复发及不良反应等情况,对结果进行统计分析。结果：治疗组有效率为82.2%,对照组为61.67%,治疗组较对照组对面部色斑治疗占明显优势（P=0.014）,并未见不良反应。结论：氨甲环酸片联合Q开关YAG激光治疗面部黄褐斑疗效好,适合临床应用。     

氨甲环酸片联合Q开关YAG激光治疗黄褐斑疗效观察

目的:观察氨甲环酸片联合Q开关YAG激光对黄褐斑的治疗效果。方法:选取2006年3月～2011年3月间在我院确诊的黄褐斑患者(150例)为研究对象,随机分为治疗组和对照组,治疗组采用氨甲环酸片加Q开关YAG激光治疗,对照组仅予以Q开关YAG激光治疗,两组均同时辅以中药面膜外敷。治疗3～12个月,随访6～12个月,观察治疗后的临床效果、复发及不良反应等情况,对结果进行统计分析。结果:治疗组有效率为82.2%,对照组为61.67%,治疗组较对照组对面部色斑治疗占明显优势(P=0.014),并未见不良反应。结论:氨甲环酸片联合Q开关YAG激光治疗面部黄褐斑疗效好,适合临床应用。     

氨甲环酸联合Q开关Nd∶YAG激光治疗黄褐斑疗效观察

目的研究口服氨甲环酸联合Q开关Nd∶YAG激光治疗黄褐斑的临床疗效和安全性。方法 57例黄褐斑患者随机分为试验组和对照组,试验组在接受Nd∶YAG激光治疗的同时口服氨甲环酸片12周,对照组仅接受Nd∶YAG激光治疗。治疗后4、8、12周对患者进行黄褐斑皮损面积和严重度指数(MASI)评分,观察临床治疗效果并记录不良反应。结果随着治疗时间增加,患者的MASI评分逐渐下降。治疗后8周、12周,试验组和对照组患者MASI评分比较差异有统计学意义(P0.05)。两组患者无明显不良反应发生。结论 Q开关Nd∶YAG激光联合氨甲环酸口服治疗黄褐斑安全有效,且不良反应少。     

红宝石点阵激光联合氨甲环酸治疗黄褐斑临床观察

目的 对红宝石点阵激光联合氨甲环酸片治疗黄褐斑进行临床疗效观察。方法 激光治疗:采用点阵模式,能量密度2.5～3.5J/cm2,每隔2周治疗1次,2个月为1个疗程;同时口服氨甲环酸片500mg,1次/d,2个月为1个疗程,连续治疗3个疗程;对患者进行黄褐斑皮损面积和严重程度指数(MASI)评分,采用自身治疗前/后对照法进行疗效观察,记录起效时间、复发情况及不良反应等。结果 120例患者经过半年的治疗后,并随访半年至1年,118例患者出现了不同程度的色斑减轻,有效率为65.84%。停止治疗后8例患者出现色斑复发,7例患者在服药期间感觉月经量减少,未发现明显炎症后色素沉着及其他不良反应的发生。结论 红宝石点阵激光联合氨甲环酸片治疗黄褐斑是一种疗效显著,且安全性高的治疗方法。     

Q开关1064nm激光联合口服氨甲环酸片治疗黄褐斑的疗效及安全性探讨

目的 观察氨甲环酸片联合Q开关1 064nm激光治疗黄褐斑的疗效及安全性.方法 选取2017年3月至2019年12月在某医院皮肤科接受治疗的80例黄褐斑患者作为研究对象,随机分为两组:观察组40例患者实施Q开关1 064nm激光联合氨甲环酸片治疗;对照组40例患者单独实施Q开关1 064nm激光治疗.比较两组患者治疗前...     

Q开关755 nm紫翠宝石激光联合氨甲环酸外用治疗面部黄褐斑25例疗效观察

目的 研究Q755紫翠宝石激光联合外用氨甲环酸治疗面部黄褐斑的临床疗效。方法 选取浙江省荣军医院皮肤科2020年3—5月就诊的黄褐斑患者50例,随机分为治疗组及对照组,每组25例。治疗组采用调Q755紫翠宝石激光5 mm光斑,1.6 J/cm²能量,70 ns脉宽的模式对皮损进行照射,2周1次,治疗6次,同时外涂氨甲环酸精华液,早晚各1次,连续6个月;对照组局部使用氨甲环酸精华液,早晚1次,连续使用6个月。2组同时保湿防晒。疗程结束后观察黄褐斑面积及严重指数(MASI)以及医患双方主观评价。统计学分析,计量资料采用独立样本t检验,计数资料采用χ²检验。结果 治疗前MASI评分治疗组(19.66±10.11),对照组(20.29±9.90),2组患者MASI评分比较差异无统计学意义(P=0.824),治疗后MASI评分治疗组(9.54±5.04)明显低于对照组(13.79±4.51),差异有统计学意义(P=0.003)。治疗前后治疗组患者MASI评分明显低于治疗前,差异有统计学意义(P=0.000),治疗前后对照组患者MASI评分差异有统计学意...     

Q开关1064nm激光联合中医药治疗黄褐斑的疗效观察

目的 探究Q开关1064nm激光联合中医药治疗黄褐斑的疗效.方法 选择某院2020年2月至2021年2月收治的黄褐斑患者共72例,随机分为观察组(Q开关1064nm激光联合中医药治疗)及对照组(Q开关1064nm激光治疗),均为36例.比较两组患者的氧化应激指标、生活质量、临床疗效和皮肤状况等.结果 观察组的过氧化氢酶...     

调Q 1064nm 点阵激光联合氨甲环酸治疗黄褐斑的临床观察

目的:评价调Q 1064 nm点阵激光联合口服氨甲环酸治疗黄褐斑的临床疗效和安全性。方法:将入选的90例黄褐斑患者随机分为3组,每组30例。治疗组接受调Q 1064 nm点阵激光联合口服氨甲环酸,对照组1单独接受调Q 1064 nm点阵激光治疗,对照组2仅接受氨甲环酸治疗。调Q点阵激光治疗为1次/月,6次为1疗程;氨甲环酸胶囊口服,250 mg/次,2次/d,疗程6个月。每月随访1次,治疗结束后6个月比较三组患者的临床疗效并记录不良反应。结果:治疗结束6个月后,治疗组、对照组1、对照组2的有效率分别为86.67%、56.67%和60.00%,治疗组有效率高于对照组1、对照组2,差异均有统计学意义(χ~2值分别为6.65、5.46,P值均0.05)。三组均有个别病例出现轻微不良反应,均可耐受。结论:调Q 1064 nm点阵激光联合氨甲环酸治疗黄褐斑安全有效,疗效优于单用调Q1064 nm点阵激光或者单用氨甲环酸。     

红宝石点阵激光联合强脉冲光治疗黄褐斑102例疗效评价

目的:评价红宝石点阵激光联合强脉冲激光治疗黄褐斑临床疗效及安全性。方法:102例黄褐斑患者给予Q开关红宝石点阵激光治疗,能量密度2.5~3.5 J/cm2,2周后,行强脉冲光治疗。每4周治疗1次,共4次。治疗结束前后对患者进行黄褐斑皮损面积和严重程度指数(MASI)评分,记录复发情况及不良反应。治疗结束后6个月随访判定结果。结果:痊愈5例(4.90%),显效69例(67.65%),好转26例(25.49%),无效2例(1.96%),总有效率72.55%。未见明显不良反应。结论:红宝石点阵激光联合强脉冲光治疗黄褐斑安全、有效。     

A giant melanocytic nevus treated with combined use of normal mode ruby laser and Q-switched alexandrite laser

We report a combination procedure that can improve the effectiveness of laser removal of giant congenital melanocytic nevi (CMN). A 2-year-old girl with a giant CMN was seen in our outpatient clinic. Histological findings showed a compound nevus without any evidence of malignancy or dysplastic changes. The patient was treated with the normal mode ruby laser and Q-switched alexandrite laser. The lesion was significantly improved in color and cosmetic appearance. Partial hypopigmentation and texture changes were observed. Histological findings showed a marked decrease in the number of junctional melanocytes and the nests in the papillary and reticular dermis. The combined laser treatment is an effective method for the treatment of giant CMN, but further study is warranted to follow-up questions of recurrence and malignant change.     

Comparison of a single treatment with Q-switched ruby laser and Q-switched Nd:YAG laser in removing black-blue Chinese tattoos

Abstract

Background: Black and blue are two popular colors in Chinese tattooing. Two Q-switched lasers, ruby and Nd:YAG, are effective for tattoo removal. No reference with regard to a comparison of the effects and adverse reactions in Chinese individuals has been made in the literature. Objective: To compare a single treatment of black-blue tattoos with the Q-switched ruby laser and Q-switched Nd:YAG (1064 nm) laser. Methods: A total of 35 Chinese patients with black-blue tattoos at the laser center of the Institute of Dermatology, Chinese Academy of Medical Sciences were enrolled into a self-control study. Tattoos were split into two parts or two nearby tattoos on the same body part were used; one side was treated with the Q-switched ruby laser and the other with the Q-switched Nd:YAG laser. Immediate response, treatment outcome and adverse effects were compared. The statistical significance level was set at p< 0.05. Results: Edema and exudation were more common immediately after ruby laser treatment (p< 0.05). The Q-switched Nd:YAG laser had a significant difference in tattoo lightening versus the Q-switched ruby laser after a single treatment (p<0.05). There was no significant difference in adverse effects between the two lasers. Conclusion: The Q-switched Nd:YAG laser is more effective at tattoo lightening for Chinese individuals. Its immediate response after treatment is slighter than the Q-switched ruby laser.     

Topical 3% tranexamic acid enhances the efficacy of 1064-nm Q-switched neodymium-doped yttrium aluminum garnet laser in the treatment of melasma

Background: A QS-NdYAG laser (QSNYL) and topical tranexamic acid (TA) have been widely used. However, no study has yet reported the efficacy of using both QSNYL and TA as a combined treatment for melasma. Objectives: To evaluate the efficacy and adverse effects of topical 3% TA combined with 1064-nm QSNYL as a treatment for melasma. Methods: A randomized, prospective, split-face, controlled trial was conducted. A 1064-nm QSNYL was performed on the entire face at baseline and 4 weeks later. The participants were randomly selected for application of topical 3% TA on one side of the face and the vehicle treatment on the other side of the face for 8 weeks. Clinical responses were determined by mMASI scores, Mexameter?, and participants’ evaluation. Results: Twenty-five participants completed the study. At the end of the study, the mMASI score significantly decreased in the combination treatment (p < 0.05), while no significant changes were observed in the laser-alone treatment. More than 80% of the participants noticed a >50% improvement on the side with combination therapy at every follow-up visit. No serious adverse events were reported. Conclusion: Topical TA as an adjuvant demonstrated trends of better outcomes than QSNYL alone for the treatment of melasma.     

Histological hair removal study by ruby or alexandrite laser with comparative study on the effects of wavelength and fluence

BACKGROUND: Several different laser systems are currently used to remove unwanted hairs. In this study, we studied follicular changes following hair removal with ruby or alexandrite lasers at different fluences.

METHODS: Unwanted hairs were treated with a ruby laser (Chromos 694, ICN PhotonIcs, UK) at 10, 14 or 18?J/cm² or with an alexandrite laser (LPIR, Cynosure, USA) at 11, 14 or 17?J/cm². A 3?mm skin punch biopsy was taken immediately after each laser exposure and also 1 month later. Specimens were stained for histological observation. They were observed using immunohistochemistry with antibodies recognizing factor VIII related antigen or PCNA, and also by the TUNEL method. Similarly, electron microscopic observation was examined.

RESULTS: Immediately after the laser exposure, moderate follicular damage was observed following treatment with either type of laser. One month later, cystic formation of hair follicles and foreign body giant cells were observed in skin treated with either type of laser. A similar fluence with either laser treatment resulted in similar histological changes.

CONCLUSION: In this study, the histological changes following treatment with a ruby or an alexandrite laser at the same fluence are similar.     

Q开关1064 nm Nd:YAG激光治疗黄褐斑所致点状色素减退研究进展

大光斑低能量Q开关1064 nm Nd:YAG(QSNY)激光治疗黄褐斑疗效确切,其副作用除色素沉着外,最受关注的是点状或斑驳状色素减退,本文将对大光斑低能量Q开并1064 nm Nd:YAG激光所致的点状色素减退的成因、病理及治疗进行综述。     

Retreatment using a dual mode of low-fluence Q-switched and long-pulse Nd:YAG laser in patients with melasma aggravation after previous therapy

Background: Aggravated melasma after treatment is vulnerable to stimulation, can easily deteriorate, and may be distressing without proper management. Objective: To retrospectively assess the effectiveness and safety of combination therapy using low-fluence Q-switched neodymium-doped yttrium aluminum garnet (Nd:YAG) laser (QSNY) and long-pulse Nd:YAG laser (LPNY) (dual toning) in patients with rebound melasma. Materials and methods: A total of 30 patients with aggravated melasma after previous therapy who were treated with dual toning were enrolled. A total of 10 sessions were conducted at 1-week intervals, followed by maintenance treatment. The results were evaluated using the modified Melasma Area and Severity Index (mMASI) and the physician's global assessment (PGA) before and 2 months after completing the 10 treatment sessions. Results: The baseline mMASI was 10.48 ± 3.64, which significantly decreased to 3.22 ± 1.45 2 months after completing the 10 treatment sessions (p < 0.001). Twenty-four patients (80%) had PGA grade 4 (76–100% improvement) and 6 patients (20%) had PGA grade 3 (51–75% improvement). Conclusion: Dual toning may be a safe and effective salvage treatment for patients with aggravated melasma after previous treatment. LPNY may stabilize melasma activity to prevent rebound hyperpigmentation via dermal remodeling.